{"gene":"BLK","run_date":"2026-04-28T17:12:38","timeline":{"discoveries":[{"year":1990,"finding":"BLK (B lymphoid kinase) encodes a 55 kDa Src-family protein tyrosine kinase specifically expressed in B lymphoid cells; the protein exhibits tyrosine kinase activity when expressed in bacterial cells.","method":"cDNA cloning, in vitro kinase activity assay in bacterial expression system","journal":"Science","confidence":"High","confidence_rationale":"Tier 1 — original biochemical characterization with in vitro kinase assay; foundational paper with 238 citations","pmids":["2404338"],"is_preprint":false},{"year":1992,"finding":"BLK gene expression is regulated during B-cell development: blk RNA is expressed in pro-B, pre-B, and mature B cells but is absent from plasma cell lines; this developmental-stage specificity is regulated at least in part by changes in transcription rate.","method":"Nuclear run-on transcription assay, primer extension, S1 nuclease protection, immunolocalization","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 2 — multiple orthogonal methods (run-on, nuclease protection, immunolocalization) in single study","pmids":["1537861"],"is_preprint":false},{"year":1993,"finding":"BLK tyrosine kinase activity is required for anti-IgM-mediated growth inhibition and apoptosis in B-cell lymphoma; antisense oligonucleotides to blk prevent anti-mu-chain-mediated growth arrest and apoptosis without affecting TGF-β-mediated arrest.","method":"Antisense oligonucleotide knockdown, cell growth inhibition assay, in vitro kinase assay","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — antisense knockdown with specific phenotypic readout and kinase activity measurement","pmids":["7690139"],"is_preprint":false},{"year":1993,"finding":"The SH2 domains of BLK, Lyn, and Fyn(T) bind distinct sets of phosphoproteins from B lymphocytes in a phosphotyrosine-dependent manner; BLK SH2 domain preferentially binds phosphoproteins of 90, 130, and 150 kDa whose tyrosine phosphorylation increases after antigen receptor cross-linking.","method":"SH2 domain pulldown assay from B-cell lysates, phosphoamino acid analysis, chimeric SH2 domain binding assays","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1 — in vitro pulldown with chimeric domain mutagenesis and phosphoamino acid analysis","pmids":["8226767"],"is_preprint":false},{"year":1994,"finding":"The BLK promoter is specifically bound by the B-cell-specific activator protein BSAP (PAX5), which acts as a positive transcriptional regulator of BLK expression in B-lymphoid cells.","method":"Gel mobility shift assay, competition with known BSAP sites, anti-BSAP antibody supershift, transient transfection reporter assay","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal binding and functional assays identifying BSAP as BLK promoter activator","pmids":["8195169"],"is_preprint":false},{"year":1994,"finding":"Proteins binding to BLK and Fyn SH2 domains are constitutively tyrosine-phosphorylated in unstimulated pre-B cells, but only appear upon antigen-receptor ligation in mature B cells, suggesting distinct constitutive signaling through the pre-BCR.","method":"SH2 domain pulldown from pre-B and B cell lysates (unstimulated and anti-IgM stimulated)","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"Medium","confidence_rationale":"Tier 3 — single pulldown method, but provides novel mechanistic insight into pre-BCR signaling context","pmids":["7514299"],"is_preprint":false},{"year":1996,"finding":"BLK preferentially phosphorylates peptide substrates with the consensus I/L-Y-D/E-X-L, resembling ITAM motifs found in Igα and Igβ components of the B-cell receptor; BLK requires hydrophobic residue (I/L) at position −1 and negatively charged residue at position +1 relative to the phosphorylated tyrosine.","method":"Phage display peptide library selection after in vitro phosphorylation, substrate sequence enrichment analysis","journal":"Journal of Molecular Biology","confidence":"High","confidence_rationale":"Tier 1 — phage display with in vitro kinase assay; rigorous substrate specificity determination","pmids":["8709147"],"is_preprint":false},{"year":1998,"finding":"Activated BLK expression in early B and T lymphoid progenitors induces malignant transformation: constitutively active Blk(Y495F) transgenic mice develop B lymphoid tumors with pro-B/pre-B phenotype and clonal thymic lymphomas, indicating BLK controls proliferation during lymphocyte development.","method":"Transgenic mouse model with constitutively active Blk(Y495F) mutant; tumor phenotyping by flow cytometry","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — in vivo gain-of-function model with specific tumor phenotype and clonality analysis","pmids":["9636152"],"is_preprint":false},{"year":1998,"finding":"CD72 ligation on B cells activates Lyn and BLK (but not Syk) tyrosine kinases, while also activating BTK; BTK can substitute for Syk in inducing PLC-γ2 tyrosine phosphorylation and calcium mobilization in CD72-stimulated B cells.","method":"In vitro kinase assay on immunoprecipitated BLK and Lyn from CD72-ligated B cells; comparison with BCR signaling","journal":"Journal of Immunology","confidence":"Medium","confidence_rationale":"Tier 2 — kinase activity measured by in vitro assay with immunoprecipitation","pmids":["9531290"],"is_preprint":false},{"year":1999,"finding":"Activated BLK is preferentially degraded by the ubiquitin-proteasome pathway; its ubiquitination is mediated by E6AP (an E3 ubiquitin protein ligase), establishing ubiquitin-mediated proteolysis as a regulatory mechanism for BLK activity.","method":"Co-immunoprecipitation of E6AP with Src-family kinases, ubiquitination assay, proteasome inhibitor experiments","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 2 — Co-IP plus functional ubiquitination assay; replicated with multiple Src family members","pmids":["10449731"],"is_preprint":false},{"year":1999,"finding":"AML1 (RUNX1) binds specifically to a site in the BLK promoter through its runt DNA-binding domain and physically interacts with the paired DNA-binding domain of BSAP; AML1 and BSAP synergistically activate BLK promoter transcription by more than 50-fold.","method":"Gel mobility shift assay, in vitro binding/pulldown, transient transfection reporter assay","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro protein-protein interaction plus functional synergy demonstrated by reporter assay","pmids":["10455134"],"is_preprint":false},{"year":1998,"finding":"NF-κB/p50 homodimer interacts with a sequence overlapping the PAX5 binding site on the BLK promoter in LPS-activated B cells and plasma cells; p50 homodimers and p50/p65 heterodimers have opposing effects on BLK transcription, providing a mechanism for differential regulation during B-cell development.","method":"Electrophoretic mobility shift assay (EMSA), site-specific mutagenesis, CAT reporter transfection, PAX5 overexpression","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — EMSA with antibody identification, mutagenesis of binding site, and functional reporter assay","pmids":["9660839"],"is_preprint":false},{"year":2000,"finding":"BLK is dispensable for B-cell development, in vitro activation, and humoral immune responses to T-cell-dependent and -independent antigens in mice; Blk knockout mice show no B-cell phenotype, consistent with functional redundancy among Src family kinases.","method":"Gene targeting/knockout mouse model, B-cell subset analysis, in vitro activation assays, immunization experiments","journal":"Molecular and Cellular Biology","confidence":"High","confidence_rationale":"Tier 2 — complete knockout with comprehensive phenotypic analysis; independently generated mouse model","pmids":["10648608"],"is_preprint":false},{"year":2003,"finding":"Activated BLK mimics pre-BCR signaling: expression of an active Blk mutant in B progenitors causes proliferation, supports maturation beyond the pro-B stage in pre-BCR-deficient mice, suppresses VH-to-DJH rearrangement, relieves selection for productive heavy-chain rearrangement, stimulates kappa rearrangement, and induces tyrosine phosphorylation of Igβ and Syk.","method":"Transgenic active Blk expression in pre-BCR-deficient mice; flow cytometry for B-cell subsets; tyrosine phosphorylation analysis","journal":"The Journal of Experimental Medicine","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis in vivo with multiple defined phenotypic readouts; strong mechanistic study","pmids":["14662906"],"is_preprint":false},{"year":2004,"finding":"NERF-2 (ELF-2 isoform) physically interacts with AML1 via a basic region upstream of the Ets domain to cooperatively activate the BLK promoter; the inhibitory isoform NERF-1a interacts with AML1 via the same domain to repress AML1-mediated BLK transcription.","method":"In vitro binding assay, co-immunoprecipitation, transient transfection reporter assay, domain mapping","journal":"The Journal of Biological Chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro binding confirmed with functional reporter; domain mapping of interaction sites","pmids":["14970218"],"is_preprint":false},{"year":2009,"finding":"BLK is expressed in pancreatic beta cells where it enhances insulin synthesis and secretion in response to glucose by up-regulating transcription factors Pdx1 and Nkx6.1; the Ala71Thr mutation greatly attenuates these functions.","method":"BLK expression in beta cell lines, glucose-stimulated insulin secretion assay, Pdx1/Nkx6.1 reporter assay, mutagenesis","journal":"Proceedings of the National Academy of Sciences of the United States of America","confidence":"High","confidence_rationale":"Tier 1–2 — functional cell-based assays with mutagenesis showing mechanism; foundational paper for BLK in beta cells","pmids":["19667185"],"is_preprint":false},{"year":2011,"finding":"BLK and BANK1 physically interact (co-immunoprecipitate) in Daudi cells and primary naive B cells; this interaction is enhanced upon BCR stimulation with anti-IgM antibodies.","method":"Co-immunoprecipitation, confocal microscopy co-localization","journal":"Annals of the Rheumatic Diseases","confidence":"Medium","confidence_rationale":"Tier 2 — reciprocal Co-IP with stimulus-dependence shown; co-localization confirmed by microscopy","pmids":["21978998"],"is_preprint":false},{"year":2011,"finding":"BLK haploinsufficiency and deficiency impair the generation of marginal zone (MZ) B cells; MZ B cells from Blk-mutant mice are hyper-responsive to BCR stimulation both in vitro and in vivo, revealing a role for BLK in MZ B-cell development and activation threshold.","method":"Blk heterozygous and knockout mouse analysis, flow cytometry for B-cell subsets, in vitro BCR stimulation assays","journal":"Immunology and Cell Biology","confidence":"High","confidence_rationale":"Tier 2 — clean genetic model with multiple readouts (development + functional response); moderate evidence","pmids":["21894171"],"is_preprint":false},{"year":2012,"finding":"BCR-ABL downregulates BLK through c-Myc in CML leukemic stem cells; BLK functions as a tumor suppressor in leukemic stem cells through a pathway involving upstream regulator Pax5 and downstream effector p27, suppressing LSC function without affecting normal hematopoietic stem cells.","method":"Retroviral gene expression, shRNA knockdown in CML mouse model, genetic epistasis (Pax5-BLK-p27), human CML stem cell proliferation assay","journal":"Nature Genetics","confidence":"High","confidence_rationale":"Tier 2 — epistasis pathway defined in vivo with multiple molecular and cellular readouts; replicated in human cells","pmids":["22797726"],"is_preprint":false},{"year":2012,"finding":"The SLE-associated Ala71Thr substitution in BLK decreases protein half-life; NFκB p50 and p65 bind to an associated 1.2 kb haplotype segment in the BLK promoter region, with the risk haplotype showing reduced BLK mRNA levels.","method":"Protein stability assay with cycloheximide and western blot, ChIP-qPCR for NF-κB binding, transfection of BLK constructs in HEK293 cells","journal":"Annals of the Rheumatic Diseases","confidence":"High","confidence_rationale":"Tier 1–2 — protein stability assay with mutagenesis plus ChIP validation; multiple orthogonal methods","pmids":["22696686"],"is_preprint":false},{"year":2013,"finding":"BANK1 and BLK act through phospholipase C gamma 2 (PLCγ2) in B-cell signaling: PLCγ2 interacts with BANK1 (identified by Y2H), and BLK kinase activity enhances BANK1-PLCγ2 binding; interaction is suppressed upon BLK depletion and requires specific tyrosine and proline residues on BANK1.","method":"Yeast two-hybrid, co-immunoprecipitation, mutational analysis of BANK1 tyrosine/proline residues, BCR stimulation","journal":"PloS one","confidence":"High","confidence_rationale":"Tier 1–2 — Y2H confirmed by Co-IP with mutational analysis; multiple orthogonal methods","pmids":["23555801"],"is_preprint":false},{"year":2014,"finding":"BLK acts downstream of activated Gα13 to phosphorylate p190RhoGAP, causing RhoA inactivation and deficient cell invasion in response to CXCL12; BLK binds Gα13, and BLK-mediated p190RhoGAP phosphorylation upon Gα13 activation correlates with weakening of Gα13-BLK association and increased BLK-p190RhoGAP assembly.","method":"RNAi knockdown, protein overexpression, co-immunoprecipitation, RhoA activation assay, invasion assay","journal":"Cellular Signalling","confidence":"High","confidence_rationale":"Tier 2 — Co-IP defining complex assembly, RNAi epistasis, functional invasion assay; multiple orthogonal methods","pmids":["25025568"],"is_preprint":false},{"year":2015,"finding":"BLK risk haplotype (associated with reduced BLK expression) leads to lower basal BCR signaling but hyperactivatable B cells: enhanced CD86 up-regulation after BCR crosslinking, greater T cell stimulatory capacity, and increased isotype-switched memory B cells.","method":"Primary human B cells from RA patients/healthy donors stratified by BLK haplotype, flow cytometry, BCR crosslinking assays, cell culture","journal":"Arthritis & Rheumatology","confidence":"Medium","confidence_rationale":"Tier 2 — primary human cells with genotype stratification and multiple functional readouts; single-center study","pmids":["26246128"],"is_preprint":false},{"year":2015,"finding":"A BLK variant (L3P) found in CVID patients causes reduced BCR crosslinking-induced Syk phosphorylation, impaired B-cell proliferation, accelerated destruction of BCR-internalized antigen, and reduced ability to elicit antigen-specific CD4+ T-cell responses.","method":"Functional analysis of L3P-BLK in primary B cells and B-LCLs, Syk phosphorylation assay, antigen presentation assay, proliferation assay","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — natural variant with multiple functional readouts in primary human cells","pmids":["25926555"],"is_preprint":false},{"year":2016,"finding":"The Ala71Thr variant in BLK SH3 domain causes hyperphosphorylation and kinase activation, leading to enhanced ubiquitination and proteasomal degradation (reduced protein half-life by half); the 71Thr variant also severely reduces binding to the adaptor protein BANK1.","method":"In vitro protein stability assay, ubiquitination assay, co-immunoprecipitation of BLK and BANK1, mutagenesis","journal":"Genes and Immunity","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis + protein stability + ubiquitination + Co-IP; multiple orthogonal methods in single study","pmids":["26821283"],"is_preprint":false},{"year":2016,"finding":"Ibrutinib inhibits pre-BCR+ B-ALL progression by targeting both BTK and BLK; CRISPR-Cas9 gene editing of BTK and BLK individually demonstrated both are relevant ibrutinib targets in pre-BCR+ ALL, with inhibition deactivating PI3K/Akt signaling and reducing BCL6 levels.","method":"CRISPR-Cas9 gene editing, drug sensitivity assays, PI3K/Akt signaling analysis, mouse xenograft model","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 — CRISPR-Cas9 genetic validation of BLK as ibrutinib target in vivo and in vitro","pmids":["28031181"],"is_preprint":false},{"year":2016,"finding":"Bakuchiol directly binds to BLK kinase in an ATP-competitive manner and inhibits EGF-induced signaling pathways including MEK/ERK, p38 MAPK/MSK1, and AKT/p70S6K downstream of BLK.","method":"Kinase profiling, direct binding assay (ATP-competitive), in vitro kinase assay, in vivo xenograft","journal":"Oncotarget","confidence":"Medium","confidence_rationale":"Tier 2 — direct binding and kinase assay; but primarily a pharmacological study with BLK as one of multiple targets","pmids":["26910280"],"is_preprint":false},{"year":2019,"finding":"Rare missense variants in BLK found in SLE patients (but not controls) impair suppression of IRF5 and type-I IFN in human B cell lines and increase pathogenic lymphocytes in lupus-prone mice; BLK and BANK1 interact physically and functionally to regulate these pathways.","method":"Functional assay of rare variants in B cell lines (IRF5/IFN suppression), lupus-prone mouse model with variant introduction, Co-IP","journal":"Nature Communications","confidence":"High","confidence_rationale":"Tier 2 — functional validation of specific rare variants in human B cells and in vivo mouse model; strong evidence","pmids":["31101814"],"is_preprint":false},{"year":2023,"finding":"BLK phosphorylates IRF3 at tyrosine 107 following viral infection; BLK first undergoes autophosphorylation at Y309 upon viral infection, then directly binds and phosphorylates IRF3-Y107, which promotes TBK1-induced IRF3 S386/S396 phosphorylation and downstream antiviral response; BLK-deficient mice show lower serum cytokines and higher lethality after VSV infection.","method":"In vitro kinase assay, mutagenesis (Y309 and Y107), co-immunoprecipitation, BLK knockout cells and mice, viral infection models","journal":"PLoS Pathogens","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay with site mutagenesis, Co-IP, and in vivo validation; multiple orthogonal methods","pmids":["37871014"],"is_preprint":false},{"year":2023,"finding":"BLK is pre-associated with IL1R1 and IL1RAcP in resting cells; IL-1β stimulation induces BLK autophosphorylation at Y309, after which activated BLK directly phosphorylates TOLLIP at Y76/86/152, promoting TOLLIP dissociation from IRAK1 and facilitating TLR/IL-1R-mediated signal transduction.","method":"Co-immunoprecipitation, in vitro kinase assay, mutagenesis (Y309, Y76/86/152), BLK-deficient mice (IL-1β challenge), signaling analysis","journal":"The Journal of Cell Biology","confidence":"High","confidence_rationale":"Tier 1–2 — in vitro kinase assay with site mutagenesis, Co-IP of receptor complex, in vivo validation; multiple orthogonal methods","pmids":["38078859"],"is_preprint":false},{"year":2023,"finding":"BLK forms a complex with CLDN6 via the C-terminal cytoplasmic domain through direct protein-protein interaction (independent of phosphotyrosine); BLK is essential for CLDN6-triggered epithelial differentiation and retinoid acid receptor target gene expression.","method":"Immunoprecipitation, pull-down assay with recombinant proteins, CRISPR knockout of Blk in F9:Cldn6 cells, gene expression analysis","journal":"Cells","confidence":"High","confidence_rationale":"Tier 1–2 — recombinant protein pulldown confirming direct binding + CRISPR knockout with functional readout","pmids":["37443730"],"is_preprint":false},{"year":2025,"finding":"BLK is activated by FAK through complex formation in TGF-β1-induced endometrial stromal cells; FAK-BLK complex formation leads to BLK phospho-activation, which drives endoplasmic reticulum stress (GRP78/CHOP upregulation) and endometrial fibrosis; BLK knockdown attenuates fibrosis in vitro and in an intrauterine adhesion mouse model.","method":"Co-immunoprecipitation (FAK-BLK complex), siRNA knockdown, in vivo Blk knockdown mouse model, ERS marker analysis","journal":"Cell & Bioscience","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP and in vivo knockdown with defined molecular pathway; single study","pmids":["41174819"],"is_preprint":false},{"year":2002,"finding":"Mouse DAM1 interacts with BLK (identified by yeast two-hybrid) and confirmed by in vitro protein binding assay; co-expression of mDAM1 and BLK increases cell death compared to BLK alone in mammary epithelial cells, indicating mDAM1 promotes BLK pro-apoptotic function.","method":"Yeast two-hybrid screening, in vitro protein binding assay, stable transfection, cell death assay","journal":"Cancer Letters","confidence":"Medium","confidence_rationale":"Tier 3 — Y2H confirmed by in vitro binding with functional co-expression data; single study","pmids":["12406557"],"is_preprint":false},{"year":2014,"finding":"Two lupus-associated BLK promoter variants are functionally causal: rs922483 in the proximal BLK promoter reduces promoter activity and modulates alternative promoter usage; rs1382568 (tri-allelic) in the upstream alternative BLK promoter alters promoter activity in B progenitor cell lines.","method":"Trans-population mapping, sequencing, luciferase reporter assay in B cell lines","journal":"American Journal of Human Genetics","confidence":"High","confidence_rationale":"Tier 2 — functional promoter reporter assay with two independent variants; cell-type-specific validation","pmids":["24702955"],"is_preprint":false}],"current_model":"BLK is a B-lymphoid-specific Src-family non-receptor tyrosine kinase whose expression is controlled by BSAP/PAX5, AML1/RUNX1, NF-κB, and NERF/ELF-2 transcription factors; it signals downstream of the BCR and pre-BCR (phosphorylating Igβ and activating Syk), interacts physically with BANK1 (via its SH3 domain) and PLCγ2 to regulate B-cell activation, is degraded by E6AP-mediated ubiquitin-proteasome proteolysis when activated, phosphorylates IRF3 at Y107 and TOLLIP at Y76/86/152 to promote antiviral and TLR/IL-1R innate immune signaling, acts downstream of Gα13 to phosphorylate p190RhoGAP and inhibit RhoA-driven cell invasion, forms a complex with FAK to drive endoplasmic reticulum stress in fibrosis, and functions as a tumor suppressor in CML leukemic stem cells through a Pax5-BLK-p27 pathway."},"narrative":{"teleology":[{"year":1990,"claim":"Identification of BLK as a B-lymphoid-specific Src-family tyrosine kinase established the existence of a lineage-restricted kinase that could mediate B-cell-specific signaling events.","evidence":"cDNA cloning and in vitro kinase assay in bacterial expression system","pmids":["2404338"],"confidence":"High","gaps":["No substrates or signaling pathway identified","In vivo function unknown"]},{"year":1993,"claim":"Demonstrating that BLK kinase activity is required for anti-IgM-induced growth arrest and apoptosis in B-cell lymphoma, and that its SH2 domain binds distinct BCR-stimulated phosphoproteins, linked BLK functionally to BCR signaling.","evidence":"Antisense knockdown with growth/apoptosis readout; SH2 domain pulldowns from B-cell lysates with phosphoamino acid analysis","pmids":["7690139","8226767"],"confidence":"High","gaps":["Direct substrates not yet identified","Relationship to other Src kinases in BCR signaling unclear"]},{"year":1996,"claim":"Determination of BLK's substrate consensus motif (I/L-Y-D/E-X-L) matching Igα/Igβ ITAMs identified the likely physiological substrates linking BLK to BCR complex phosphorylation.","evidence":"Phage display peptide library selection with in vitro phosphorylation","pmids":["8709147"],"confidence":"High","gaps":["Direct phosphorylation of Igβ ITAMs not yet shown in cells","Relative contribution versus Lyn unknown"]},{"year":1998,"claim":"Mapping the transcriptional control of BLK by PAX5/BSAP, NF-κB p50/p65, and later AML1/RUNX1 and NERF-2 explained how BLK expression is restricted to B-lymphoid cells and modulated during differentiation, including downregulation in plasma cells.","evidence":"EMSA, supershift, mutagenesis, reporter assays across multiple studies; synergistic activation by AML1+BSAP (>50-fold)","pmids":["8195169","9660839","10455134","14970218"],"confidence":"High","gaps":["Epigenetic regulation not addressed","In vivo promoter occupancy dynamics during B-cell differentiation not mapped"]},{"year":1998,"claim":"Constitutively active Blk(Y495F) transgenic mice developed B-lymphoid and thymic tumors, revealing that uncontrolled BLK signaling is oncogenic during lymphoid development and establishing the need for tight regulation of BLK activity.","evidence":"Transgenic mouse model with gain-of-function Blk mutant; tumor phenotyping by flow cytometry","pmids":["9636152"],"confidence":"High","gaps":["Downstream oncogenic effectors not identified","Whether kinase-dead rescue prevents tumorigenesis not tested"]},{"year":1999,"claim":"Discovery that activated BLK is degraded via E6AP-mediated ubiquitin-proteasome proteolysis provided the mechanism for limiting BLK kinase activity, explaining how BLK turnover is coupled to its activation state.","evidence":"Co-immunoprecipitation of E6AP with Src-family kinases, ubiquitination assay, proteasome inhibitor experiments","pmids":["10449731"],"confidence":"High","gaps":["Specific ubiquitination sites on BLK not mapped","Whether E6AP loss affects B-cell phenotype through BLK stabilization not tested"]},{"year":2000,"claim":"The absence of a B-cell developmental phenotype in Blk knockout mice demonstrated functional redundancy among Src-family kinases, but left open the question of BLK's non-redundant roles.","evidence":"Gene targeting/knockout mouse with comprehensive B-cell subset and humoral immunity analysis","pmids":["10648608"],"confidence":"High","gaps":["Compound knockouts with Lyn/Fyn not tested","Marginal zone B-cell subset not specifically examined"]},{"year":2003,"claim":"Active BLK was shown to substitute for pre-BCR signaling in vivo—driving Igβ/Syk phosphorylation, B-cell maturation past the pro-B stage, and immunoglobulin gene rearrangement—establishing BLK as a critical kinase linking the pre-BCR to developmental checkpoints.","evidence":"Transgenic active Blk expression in pre-BCR-deficient mice with flow cytometry and phosphorylation analysis","pmids":["14662906"],"confidence":"High","gaps":["Whether endogenous BLK (not constitutively active) is the dominant pre-BCR kinase remains unclear","Signaling intermediates between Syk activation and gene rearrangement not defined"]},{"year":2009,"claim":"Discovery of BLK expression and function in pancreatic β-cells, where it enhances insulin synthesis/secretion by upregulating Pdx1 and Nkx6.1, expanded BLK's biological roles beyond the immune system and linked the Ala71Thr variant to impaired β-cell function.","evidence":"BLK expression in beta cell lines, glucose-stimulated insulin secretion assay, Pdx1/Nkx6.1 reporter assay, mutagenesis","pmids":["19667185"],"confidence":"High","gaps":["Direct kinase substrates in β-cells not identified","Mechanism linking BLK kinase activity to Pdx1/Nkx6.1 transcription unknown"]},{"year":2012,"claim":"BLK was identified as a tumor suppressor in CML leukemic stem cells, operating through a Pax5–BLK–p27 axis that is silenced by BCR-ABL/c-Myc, providing a mechanism for leukemic stem cell self-renewal and a rationale for reactivating BLK in CML therapy.","evidence":"Retroviral expression, shRNA knockdown in CML mouse model, genetic epistasis, human CML stem cell assays","pmids":["22797726"],"confidence":"High","gaps":["How BLK upregulates p27 mechanistically not defined","Whether BLK reactivation is therapeutically feasible not addressed"]},{"year":2013,"claim":"Elucidation of the BLK–BANK1–PLCγ2 signaling module downstream of the BCR revealed how BLK kinase activity promotes BANK1–PLCγ2 complex assembly, and how disease-associated variants in BLK and BANK1 disrupt this pathway.","evidence":"Yeast two-hybrid, co-immunoprecipitation, mutational analysis of BANK1 tyrosine/proline residues","pmids":["23555801","21978998","26821283"],"confidence":"High","gaps":["Whether BANK1 is a direct BLK substrate not proven by in vitro kinase assay","Downstream consequences of PLCγ2 activation specificity via this module not resolved"]},{"year":2014,"claim":"Identification of BLK as a Gα13 effector that phosphorylates p190RhoGAP to inactivate RhoA revealed a non-BCR signaling axis controlling cell invasion, broadening BLK's mechanistic repertoire beyond lymphocyte biology.","evidence":"RNAi knockdown, co-immunoprecipitation, RhoA activation assay, invasion assay","pmids":["25025568"],"confidence":"High","gaps":["Physiological context for Gα13–BLK axis in B cells not established","Whether this pathway operates in vivo not tested"]},{"year":2016,"claim":"CRISPR-Cas9 validation that both BLK and BTK are functional ibrutinib targets in pre-BCR+ B-ALL established BLK as a therapeutic target in acute lymphoblastic leukemia, with inhibition deactivating PI3K/Akt signaling.","evidence":"CRISPR-Cas9 gene editing of BTK and BLK individually, drug sensitivity assays, mouse xenograft model","pmids":["28031181"],"confidence":"High","gaps":["Relative contribution of BLK vs BTK inhibition to clinical ibrutinib efficacy unknown","BLK-specific inhibitors not available"]},{"year":2019,"claim":"Rare SLE-associated BLK variants were shown to impair suppression of IRF5 and type-I IFN, with BLK and BANK1 functioning together to restrain this pathway, establishing a direct mechanistic link between BLK loss-of-function and lupus pathogenesis.","evidence":"Functional assay of rare variants in human B cell lines, lupus-prone mouse model, co-immunoprecipitation","pmids":["31101814"],"confidence":"High","gaps":["How BLK kinase activity suppresses IRF5 mechanistically not defined","Whether this pathway is B-cell-intrinsic or involves other cell types not resolved"]},{"year":2023,"claim":"BLK was established as a direct kinase for IRF3 (at Y107) in antiviral innate immunity and for TOLLIP (at Y76/86/152) in TLR/IL-1R signaling, revealing BLK as a broadly active innate immune signaling kinase beyond its classical BCR role.","evidence":"In vitro kinase assays with site-directed mutagenesis, co-immunoprecipitation of receptor complexes, BLK knockout mice with viral/IL-1β challenge","pmids":["37871014","38078859"],"confidence":"High","gaps":["Cell types responsible for BLK-mediated innate immunity in vivo not defined","Whether BLK phosphorylation of IRF3 and TOLLIP occurs in the same or different cell contexts unclear"]},{"year":2025,"claim":"FAK was identified as an upstream activator that forms a complex with BLK to drive endoplasmic reticulum stress and fibrosis in endometrial stromal cells, extending BLK function to a non-immune fibrotic disease context.","evidence":"Co-immunoprecipitation of FAK-BLK, siRNA knockdown, in vivo Blk knockdown in intrauterine adhesion mouse model","pmids":["41174819"],"confidence":"Medium","gaps":["Direct FAK phosphorylation sites on BLK not mapped","Single study; independent replication needed","Whether BLK–ER stress axis operates in other fibrotic tissues not examined"]},{"year":null,"claim":"Key unresolved questions include: the structural basis for BLK's substrate selectivity versus other Src-family kinases; the identity of BLK's direct substrates linking it to Pdx1/Nkx6.1 in β-cells and to p27 in CML stem cells; and whether BLK-specific inhibitors can be developed for therapeutic applications.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal structure of BLK","No BLK-specific small-molecule inhibitor characterized","In vivo compound Src-family kinase knockouts needed to define non-redundant BLK functions"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,6,13,21,28,29]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[18,27]}],"localization":[{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[3,16,20]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[29,30]}],"pathway":[{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[13,17,27,28,29]},{"term_id":"R-HSA-5357801","term_label":"Programmed Cell Death","supporting_discovery_ids":[2,32]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[21,25,26]}],"complexes":["pre-BCR signaling complex","BANK1-BLK-PLCγ2 module","IL-1R1/IL1RAcP-BLK complex"],"partners":["BANK1","PLCG2","E6AP","FAK","CLDN6","GNA13","IRF3","TOLLIP"],"other_free_text":[]},"mechanistic_narrative":"BLK is a B-lymphoid Src-family non-receptor tyrosine kinase that transduces signals from the B-cell receptor and pre-BCR, phosphorylating Igβ ITAMs and activating Syk to regulate B-cell development, activation thresholds, and immunoglobulin gene rearrangement [PMID:14662906, PMID:8709147, PMID:25926555]. Its expression is transcriptionally controlled by PAX5/BSAP, RUNX1/AML1, NF-κB, and NERF-2/ELF-2, which synergistically regulate the BLK promoter during B-cell differentiation, while activated BLK protein is turned over via E6AP-mediated ubiquitin-proteasome degradation [PMID:8195169, PMID:10455134, PMID:10449731]. Beyond canonical BCR signaling—where BLK cooperates with BANK1 and PLCγ2 to modulate B-cell activation and suppress IRF5/type-I IFN pathways relevant to lupus [PMID:23555801, PMID:31101814]—BLK phosphorylates IRF3-Y107 to promote antiviral innate immunity and phosphorylates TOLLIP-Y76/86/152 to facilitate TLR/IL-1R signaling [PMID:37871014, PMID:38078859]. BLK also functions as a tumor suppressor in CML leukemic stem cells through a Pax5–BLK–p27 axis, acts downstream of Gα13 to phosphorylate p190RhoGAP and inhibit RhoA-driven invasion, and enhances insulin synthesis in pancreatic β-cells by upregulating Pdx1 and Nkx6.1 [PMID:22797726, PMID:25025568, PMID:19667185]."},"prefetch_data":{"uniprot":{"accession":"P51451","full_name":"Tyrosine-protein kinase Blk","aliases":["B lymphocyte kinase","p55-Blk"],"length_aa":505,"mass_kda":57.7,"function":"Non-receptor tyrosine kinase involved in B-lymphocyte development, differentiation and signaling (By similarity). B-cell receptor (BCR) signaling requires a tight regulation of several protein tyrosine kinases and phosphatases, and associated coreceptors (By similarity). Binding of antigen to the B-cell antigen receptor (BCR) triggers signaling that ultimately leads to B-cell activation (By similarity). Signaling through BLK plays an important role in transmitting signals through surface immunoglobulins and supports the pro-B to pre-B transition, as well as the signaling for growth arrest and apoptosis downstream of B-cell receptor (By similarity). Specifically binds and phosphorylates CD79A at 'Tyr-188'and 'Tyr-199', as well as CD79B at 'Tyr-196' and 'Tyr-207' (By similarity). Also phosphorylates the immunoglobulin G receptors FCGR2A, FCGR2B and FCGR2C (PubMed:8756631). With FYN and LYN, plays an essential role in pre-B-cell receptor (pre-BCR)-mediated NF-kappa-B activation (By similarity). Also contributes to BTK activation by indirectly stimulating BTK intramolecular autophosphorylation (By similarity). In pancreatic islets, acts as a modulator of beta-cells function through the up-regulation of PDX1 and NKX6-1 and consequent stimulation of insulin secretion in response to glucose (PubMed:19667185). Phosphorylates CGAS, promoting retention of CGAS in the cytosol (PubMed:30356214)","subcellular_location":"Cell membrane","url":"https://www.uniprot.org/uniprotkb/P51451/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/BLK","classification":"Not Classified","n_dependent_lines":2,"n_total_lines":1208,"dependency_fraction":0.0016556291390728477},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/BLK","total_profiled":1310},"omim":[{"mim_id":"619798","title":"E74-LIKE ETS TRANSCRIPTION FACTOR 2; ELF2","url":"https://www.omim.org/entry/619798"},{"mim_id":"613375","title":"MATURITY-ONSET DIABETES OF THE YOUNG, TYPE 11; MODY11","url":"https://www.omim.org/entry/613375"},{"mim_id":"612254","title":"SYSTEMIC LUPUS ERYTHEMATOSUS, SUSCEPTIBILITY TO, 12; SLEB12","url":"https://www.omim.org/entry/612254"},{"mim_id":"611775","title":"KAWASAKI DISEASE","url":"https://www.omim.org/entry/611775"},{"mim_id":"610085","title":"FAMILY WITH SEQUENCE SIMILARITY 167, MEMBER A; FAM167A","url":"https://www.omim.org/entry/610085"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Uncertain","locations":[{"location":"Nucleoplasm","reliability":"Uncertain"}],"tissue_specificity":"Group enriched","tissue_distribution":"Detected in some","driving_tissues":[{"tissue":"intestine","ntpm":40.2},{"tissue":"lymphoid tissue","ntpm":49.9}],"url":"https://www.proteinatlas.org/search/BLK"},"hgnc":{"alias_symbol":["MGC10442"],"prev_symbol":[]},"alphafold":{"accession":"P51451","domains":[{"cath_id":"2.30.30.40","chopping":"63-120","consensus_level":"high","plddt":88.0803,"start":63,"end":120},{"cath_id":"3.30.505.10","chopping":"123-208","consensus_level":"high","plddt":89.9855,"start":123,"end":208},{"cath_id":"3.30.200.20","chopping":"235-315","consensus_level":"medium","plddt":87.6349,"start":235,"end":315},{"cath_id":"1.10.510.10","chopping":"322-387_398-495","consensus_level":"medium","plddt":92.3174,"start":322,"end":495}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P51451","model_url":"https://alphafold.ebi.ac.uk/files/AF-P51451-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P51451-F1-predicted_aligned_error_v6.png","plddt_mean":81.56},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=BLK","jax_strain_url":"https://www.jax.org/strain/search?query=BLK"},"sequence":{"accession":"P51451","fasta_url":"https://rest.uniprot.org/uniprotkb/P51451.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P51451/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P51451"}},"corpus_meta":[{"pmid":"18204098","id":"PMC_18204098","title":"Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX.","date":"2008","source":"The New England journal of medicine","url":"https://pubmed.ncbi.nlm.nih.gov/18204098","citation_count":743,"is_preprint":false},{"pmid":"2404338","id":"PMC_2404338","title":"Specific expression of a tyrosine kinase gene, blk, in B lymphoid cells.","date":"1990","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/2404338","citation_count":238,"is_preprint":false},{"pmid":"10449731","id":"PMC_10449731","title":"Regulation of the Src family tyrosine kinase Blk through E6AP-mediated ubiquitination.","date":"1999","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10449731","citation_count":134,"is_preprint":false},{"pmid":"19667185","id":"PMC_19667185","title":"Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction.","date":"2009","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/19667185","citation_count":134,"is_preprint":false},{"pmid":"8709147","id":"PMC_8709147","title":"Catalytic specificity of phosphotyrosine kinases Blk, Lyn, c-Src and Syk as assessed by phage display.","date":"1996","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8709147","citation_count":118,"is_preprint":false},{"pmid":"19796918","id":"PMC_19796918","title":"Association of the C8orf13-BLK region with systemic sclerosis in North-American and European populations.","date":"2009","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/19796918","citation_count":106,"is_preprint":false},{"pmid":"14749373","id":"PMC_14749373","title":"Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death.","date":"2004","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/14749373","citation_count":99,"is_preprint":false},{"pmid":"20861858","id":"PMC_20861858","title":"Association of EBF1, FAM167A(C8orf13)-BLK and TNFSF4 gene variants with primary Sjögren's syndrome.","date":"2010","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/20861858","citation_count":98,"is_preprint":false},{"pmid":"9525867","id":"PMC_9525867","title":"Blk, a BH3-containing mouse protein that interacts with Bcl-2 and Bcl-xL, is a potent death agonist.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9525867","citation_count":90,"is_preprint":false},{"pmid":"31101814","id":"PMC_31101814","title":"Functional rare and low frequency variants in BLK and BANK1 contribute to human lupus.","date":"2019","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/31101814","citation_count":88,"is_preprint":false},{"pmid":"28031181","id":"PMC_28031181","title":"Ibrutinib inhibits pre-BCR+ B-cell acute lymphoblastic leukemia progression by targeting BTK and BLK.","date":"2016","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/28031181","citation_count":72,"is_preprint":false},{"pmid":"21905002","id":"PMC_21905002","title":"Gene-gene interaction of BLK, TNFSF4, TRAF1, TNFAIP3, and REL in systemic lupus erythematosus.","date":"2012","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21905002","citation_count":70,"is_preprint":false},{"pmid":"1537861","id":"PMC_1537861","title":"Structure and developmental regulation of the B-lymphoid tyrosine kinase gene blk.","date":"1992","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/1537861","citation_count":67,"is_preprint":false},{"pmid":"10648608","id":"PMC_10648608","title":"The B-cell-specific Src-family kinase Blk is dispensable for B-cell development and activation.","date":"2000","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10648608","citation_count":65,"is_preprint":false},{"pmid":"21978998","id":"PMC_21978998","title":"Genetic and physical interaction of the B-cell systemic lupus erythematosus-associated genes BANK1 and BLK.","date":"2011","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/21978998","citation_count":64,"is_preprint":false},{"pmid":"19644876","id":"PMC_19644876","title":"Association of STAT4 and BLK, but not BANK1 or IRF5, with primary antiphospholipid syndrome.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19644876","citation_count":63,"is_preprint":false},{"pmid":"22797726","id":"PMC_22797726","title":"The Blk pathway functions as a tumor suppressor in chronic myeloid leukemia stem cells.","date":"2012","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22797726","citation_count":63,"is_preprint":false},{"pmid":"8195169","id":"PMC_8195169","title":"Specific recognition of the blk promoter by the B-lymphoid transcription factor B-cell-specific activator protein.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8195169","citation_count":60,"is_preprint":false},{"pmid":"14662906","id":"PMC_14662906","title":"Mimicry of pre-B cell receptor signaling by activation of the tyrosine kinase Blk.","date":"2003","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/14662906","citation_count":59,"is_preprint":false},{"pmid":"7690139","id":"PMC_7690139","title":"Antisense oligodeoxynucleotides to the blk tyrosine kinase prevent anti-mu-chain-mediated growth inhibition and apoptosis in a B-cell lymphoma.","date":"1993","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7690139","citation_count":59,"is_preprint":false},{"pmid":"35108381","id":"PMC_35108381","title":"Evaluation of Evidence for Pathogenicity Demonstrates That BLK, KLF11, and PAX4 Should Not Be Included in Diagnostic Testing for MODY.","date":"2022","source":"Diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/35108381","citation_count":55,"is_preprint":false},{"pmid":"9636152","id":"PMC_9636152","title":"Malignant transformation of early lymphoid progenitors in mice expressing an activated Blk tyrosine kinase.","date":"1998","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/9636152","citation_count":55,"is_preprint":false},{"pmid":"10455134","id":"PMC_10455134","title":"AML1 (CBFalpha2) cooperates with B cell-specific activating protein (BSAP/PAX5) in activation of the B cell-specific BLK gene promoter.","date":"1999","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10455134","citation_count":54,"is_preprint":false},{"pmid":"24023612","id":"PMC_24023612","title":"Replication and meta-analysis of GWAS identified susceptibility loci in Kawasaki disease confirm the importance of B lymphoid tyrosine kinase (BLK) in disease susceptibility.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24023612","citation_count":53,"is_preprint":false},{"pmid":"24702955","id":"PMC_24702955","title":"Two functional lupus-associated BLK promoter variants control cell-type- and developmental-stage-specific transcription.","date":"2014","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/24702955","citation_count":53,"is_preprint":false},{"pmid":"19180478","id":"PMC_19180478","title":"Replication of the association between the C8orf13-BLK region and systemic lupus erythematosus in a Japanese population.","date":"2009","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/19180478","citation_count":48,"is_preprint":false},{"pmid":"18981230","id":"PMC_18981230","title":"The BH3-only protein Bik/Blk/Nbk inhibits nuclear translocation of activated ERK1/2 to mediate IFNgamma-induced cell death.","date":"2008","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/18981230","citation_count":46,"is_preprint":false},{"pmid":"7514299","id":"PMC_7514299","title":"Tyrosine phosphorylation of Blk and Fyn Src homology 2 domain-binding proteins occurs in response to antigen-receptor ligation in B cells and constitutively in pre-B cells.","date":"1994","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/7514299","citation_count":44,"is_preprint":false},{"pmid":"21480188","id":"PMC_21480188","title":"C8orf13-BLK is a genetic risk locus for systemic sclerosis and has additive effects with BANK1: results from a large french cohort and meta-analysis.","date":"2011","source":"Arthritis and rheumatism","url":"https://pubmed.ncbi.nlm.nih.gov/21480188","citation_count":43,"is_preprint":false},{"pmid":"7608542","id":"PMC_7608542","title":"Differential expression of the blk and ret tyrosine kinases during B lineage development is dependent on Ig rearrangement.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7608542","citation_count":43,"is_preprint":false},{"pmid":"23555801","id":"PMC_23555801","title":"BANK1 and BLK act through phospholipase C gamma 2 in B-cell signaling.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23555801","citation_count":41,"is_preprint":false},{"pmid":"26246128","id":"PMC_26246128","title":"Autoimmune disease-associated haplotypes of BLK exhibit lowered thresholds for B cell activation and expansion of Ig class-switched B cells.","date":"2015","source":"Arthritis & rheumatology (Hoboken, N.J.)","url":"https://pubmed.ncbi.nlm.nih.gov/26246128","citation_count":40,"is_preprint":false},{"pmid":"9531290","id":"PMC_9531290","title":"Activation of lyn, blk, and btk but not syk in CD72-stimulated B lymphocytes.","date":"1998","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/9531290","citation_count":36,"is_preprint":false},{"pmid":"23635951","id":"PMC_23635951","title":"Association studies of TNFSF4, TNFAIP3 and FAM167A-BLK polymorphisms with primary Sjogren's syndrome in Han Chinese.","date":"2013","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/23635951","citation_count":36,"is_preprint":false},{"pmid":"22696686","id":"PMC_22696686","title":"Fine mapping and conditional analysis identify a new mutation in the autoimmunity susceptibility gene BLK that leads to reduced half-life of the BLK protein.","date":"2012","source":"Annals of the rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/22696686","citation_count":36,"is_preprint":false},{"pmid":"8226767","id":"PMC_8226767","title":"SH2 domains of the protein-tyrosine kinases Blk, Lyn, and Fyn(T) bind distinct sets of phosphoproteins from B lymphocytes.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8226767","citation_count":35,"is_preprint":false},{"pmid":"26910280","id":"PMC_26910280","title":"Bakuchiol suppresses proliferation of skin cancer cells by directly targeting Hck, Blk, and p38 MAP kinase.","date":"2016","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26910280","citation_count":35,"is_preprint":false},{"pmid":"24637841","id":"PMC_24637841","title":"Reduced B lymphoid kinase (Blk) expression enhances proinflammatory cytokine production and induces nephrosis in C57BL/6-lpr/lpr mice.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24637841","citation_count":33,"is_preprint":false},{"pmid":"24091983","id":"PMC_24091983","title":"Variants in TNFSF4, TNFAIP3, TNIP1, BLK, SLC15A4 and UBE2L3 interact to confer risk of systemic lupus erythematosus in Chinese population.","date":"2013","source":"Rheumatology international","url":"https://pubmed.ncbi.nlm.nih.gov/24091983","citation_count":32,"is_preprint":false},{"pmid":"26420661","id":"PMC_26420661","title":"Gene-gene interaction of ATG5, ATG7, BLK and BANK1 in systemic lupus erythematosus.","date":"2015","source":"International journal of rheumatic diseases","url":"https://pubmed.ncbi.nlm.nih.gov/26420661","citation_count":31,"is_preprint":false},{"pmid":"21894171","id":"PMC_21894171","title":"Blk haploinsufficiency impairs the development, but enhances the functional responses, of MZ B cells.","date":"2011","source":"Immunology and cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/21894171","citation_count":31,"is_preprint":false},{"pmid":"14970218","id":"PMC_14970218","title":"Isoforms of the Ets transcription factor NERF/ELF-2 physically interact with AML1 and mediate opposing effects on AML1-mediated transcription of the B cell-specific blk gene.","date":"2004","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/14970218","citation_count":31,"is_preprint":false},{"pmid":"9660839","id":"PMC_9660839","title":"The transcription factor NF-kappaB/p50 interacts with the blk gene during B cell activation.","date":"1998","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/9660839","citation_count":30,"is_preprint":false},{"pmid":"23224494","id":"PMC_23224494","title":"Reassessment of the putative role of BLK-p.A71T loss-of-function mutation in MODY and type 2 diabetes.","date":"2012","source":"Diabetologia","url":"https://pubmed.ncbi.nlm.nih.gov/23224494","citation_count":29,"is_preprint":false},{"pmid":"11714762","id":"PMC_11714762","title":"Cutting edge: A/WySnJ transitional B cells overexpress the chromosome 15 proapoptotic Blk gene and succumb to premature apoptosis.","date":"2001","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/11714762","citation_count":27,"is_preprint":false},{"pmid":"23646104","id":"PMC_23646104","title":"Epistatic interaction between BANK1 and BLK in rheumatoid arthritis: results from a large trans-ethnic meta-analysis.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23646104","citation_count":24,"is_preprint":false},{"pmid":"7592787","id":"PMC_7592787","title":"Transcription of the blk gene in human B lymphocytes is controlled by two promoters.","date":"1995","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/7592787","citation_count":24,"is_preprint":false},{"pmid":"20130895","id":"PMC_20130895","title":"The association of the BLK gene with SLE was replicated in Chinese Han.","date":"2010","source":"Archives of dermatological research","url":"https://pubmed.ncbi.nlm.nih.gov/20130895","citation_count":23,"is_preprint":false},{"pmid":"7822795","id":"PMC_7822795","title":"Molecular cloning, characterization, and chromosomal localization of a human lymphoid tyrosine kinase related to murine Blk.","date":"1995","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/7822795","citation_count":23,"is_preprint":false},{"pmid":"25545785","id":"PMC_25545785","title":"The effect of inversion at 8p23 on BLK association with lupus in Caucasian population.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/25545785","citation_count":23,"is_preprint":false},{"pmid":"28670978","id":"PMC_28670978","title":"A novel BLK-induced tumor model.","date":"2017","source":"Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/28670978","citation_count":22,"is_preprint":false},{"pmid":"27114252","id":"PMC_27114252","title":"Molecular characterization and growth optimization of halo-tolerant protease producing Bacillus Subtilis Strain BLK-1.5 isolated from salt mines of Karak, Pakistan.","date":"2016","source":"Extremophiles : life under extreme conditions","url":"https://pubmed.ncbi.nlm.nih.gov/27114252","citation_count":20,"is_preprint":false},{"pmid":"27105348","id":"PMC_27105348","title":"Association of FAM167A-BLK rs2736340 Polymorphism with Susceptibility to Autoimmune Diseases: A Meta-Analysis.","date":"2016","source":"Immunological investigations","url":"https://pubmed.ncbi.nlm.nih.gov/27105348","citation_count":17,"is_preprint":false},{"pmid":"32153635","id":"PMC_32153635","title":"Association of BLK and BANK1 Polymorphisms and Interactions With Rheumatoid Arthritis in a Latin-American Population.","date":"2020","source":"Frontiers in genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32153635","citation_count":17,"is_preprint":false},{"pmid":"21152986","id":"PMC_21152986","title":"Association of BLK (rs13277113, rs2248932) polymorphism with systemic lupus erythematosus: a meta-analysis.","date":"2010","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/21152986","citation_count":16,"is_preprint":false},{"pmid":"29663334","id":"PMC_29663334","title":"The rheumatic disease-associated FAM167A-BLK locus encodes DIORA-1, a novel disordered protein expressed highly in bronchial epithelium and alveolar macrophages.","date":"2018","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/29663334","citation_count":16,"is_preprint":false},{"pmid":"25846585","id":"PMC_25846585","title":"Single nucleotide polymorphisms in the FAM167A-BLK gene are associated with polymyositis/dermatomyositis in the Han Chinese population.","date":"2015","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/25846585","citation_count":16,"is_preprint":false},{"pmid":"7845672","id":"PMC_7845672","title":"Molecular cloning and chromosomal localization of the human homologue of a B-lymphocyte specific protein tyrosine kinase (blk).","date":"1995","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/7845672","citation_count":16,"is_preprint":false},{"pmid":"20453440","id":"PMC_20453440","title":"Association of IRF5, STAT4 and BLK with systemic lupus erythematosus and other rheumatic diseases.","date":"2010","source":"Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20453440","citation_count":15,"is_preprint":false},{"pmid":"23899688","id":"PMC_23899688","title":"Polymorphisms in the FAM167A-BLK, but not BANK1, are associated with primary Sjögren's syndrome in a Han Chinese population.","date":"2013","source":"Clinical and experimental rheumatology","url":"https://pubmed.ncbi.nlm.nih.gov/23899688","citation_count":13,"is_preprint":false},{"pmid":"22748822","id":"PMC_22748822","title":"Expression of RUNX1 isoforms and its target gene BLK in childhood acute lymphoblastic leukemia.","date":"2012","source":"Leukemia research","url":"https://pubmed.ncbi.nlm.nih.gov/22748822","citation_count":13,"is_preprint":false},{"pmid":"25926555","id":"PMC_25926555","title":"Dysfunctional BLK in common variable immunodeficiency perturbs B-cell proliferation and ability to elicit antigen-specific CD4+ T-cell help.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/25926555","citation_count":13,"is_preprint":false},{"pmid":"31400706","id":"PMC_31400706","title":"Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines.","date":"2019","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31400706","citation_count":12,"is_preprint":false},{"pmid":"28925718","id":"PMC_28925718","title":"Interaction analysis between BLK rs13277113 polymorphism and BANK1 rs3733197 polymorphism, MMEL1/TNFRSF14 rs3890745 polymorphism in determining susceptibility to rheumatoid arthritis.","date":"2017","source":"Autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/28925718","citation_count":12,"is_preprint":false},{"pmid":"25025568","id":"PMC_25025568","title":"A Blk-p190RhoGAP signaling module downstream of activated Gα13 functionally opposes CXCL12-stimulated RhoA activation and cell invasion.","date":"2014","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/25025568","citation_count":11,"is_preprint":false},{"pmid":"26821283","id":"PMC_26821283","title":"The SLE variant Ala71Thr of BLK severely decreases protein abundance and binding to BANK1 through impairment of the SH3 domain function.","date":"2016","source":"Genes and immunity","url":"https://pubmed.ncbi.nlm.nih.gov/26821283","citation_count":11,"is_preprint":false},{"pmid":"22313735","id":"PMC_22313735","title":"Identify the association between polymorphisms of BLK and systemic lupus erythematosus through unlabelled probe-based high-resolution melting analysis.","date":"2012","source":"International journal of immunogenetics","url":"https://pubmed.ncbi.nlm.nih.gov/22313735","citation_count":11,"is_preprint":false},{"pmid":"32330537","id":"PMC_32330537","title":"Associations of IL6 rs1800795, BLK rs13277113, TIMP3 rs9621532, IL1RL1 rs1041973 and IL1RAP rs4624606 single gene polymorphisms with laryngeal squamous cell carcinoma.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32330537","citation_count":10,"is_preprint":false},{"pmid":"27067206","id":"PMC_27067206","title":"Association between BLK polymorphisms and susceptibility to SLE : A meta-analysis.","date":"2017","source":"Zeitschrift fur Rheumatologie","url":"https://pubmed.ncbi.nlm.nih.gov/27067206","citation_count":9,"is_preprint":false},{"pmid":"20156505","id":"PMC_20156505","title":"Role of the C8orf13-BLK region in biopsy-proven giant cell arteritis.","date":"2010","source":"Human immunology","url":"https://pubmed.ncbi.nlm.nih.gov/20156505","citation_count":9,"is_preprint":false},{"pmid":"24632671","id":"PMC_24632671","title":"Association between a C8orf13-BLK polymorphism and polymyositis/dermatomyositis in the Japanese population: an additive effect with STAT4 on disease susceptibility.","date":"2014","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/24632671","citation_count":9,"is_preprint":false},{"pmid":"38244699","id":"PMC_38244699","title":"Improvement in organic solvent resistance of keratinase BLk by directed evolution.","date":"2024","source":"Journal of biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/38244699","citation_count":9,"is_preprint":false},{"pmid":"28713926","id":"PMC_28713926","title":"Association between TNFSF4 and BLK gene polymorphisms and susceptibility to allergic rhinitis.","date":"2017","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/28713926","citation_count":9,"is_preprint":false},{"pmid":"22740142","id":"PMC_22740142","title":"Influence of BLK polymorphisms on the risk of rheumatoid arthritis.","date":"2012","source":"Molecular biology reports","url":"https://pubmed.ncbi.nlm.nih.gov/22740142","citation_count":8,"is_preprint":false},{"pmid":"37443730","id":"PMC_37443730","title":"The Src-Family Kinases SRC and BLK Contribute to the CLDN6-Adhesion Signaling.","date":"2023","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/37443730","citation_count":7,"is_preprint":false},{"pmid":"37871014","id":"PMC_37871014","title":"Tyrosine phosphorylation of IRF3 by BLK facilitates its sufficient activation and innate antiviral response.","date":"2023","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/37871014","citation_count":7,"is_preprint":false},{"pmid":"36493694","id":"PMC_36493694","title":"Halofuginone ameliorates systemic lupus erythematosus by targeting Blk in myeloid-derived suppressor cells.","date":"2022","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/36493694","citation_count":7,"is_preprint":false},{"pmid":"30468029","id":"PMC_30468029","title":"Assessment of the Clinical Heterogeneity of Kawasaki Disease Using Genetic Variants of BLK and FCGR2A.","date":"2018","source":"Korean circulation journal","url":"https://pubmed.ncbi.nlm.nih.gov/30468029","citation_count":7,"is_preprint":false},{"pmid":"32313195","id":"PMC_32313195","title":"Polymorphisms of BLK are associated with renal disorder in patients with systemic lupus erythematosus.","date":"2020","source":"Journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/32313195","citation_count":6,"is_preprint":false},{"pmid":"27088737","id":"PMC_27088737","title":"Genetic risk of TNFSF4 and FAM167A-BLK polymorphisms in children with asthma and allergic rhinitis in a Han Chinese population.","date":"2016","source":"The Journal of asthma : official journal of the Association for the Care of Asthma","url":"https://pubmed.ncbi.nlm.nih.gov/27088737","citation_count":6,"is_preprint":false},{"pmid":"22003931","id":"PMC_22003931","title":"Multifocal motor neuropathy is not associated with genetic variation in PTPN22, BANK1, Blk, FCGR2B, CD1A/E, and TAG-1 genes.","date":"2011","source":"Journal of the peripheral nervous system : JPNS","url":"https://pubmed.ncbi.nlm.nih.gov/22003931","citation_count":6,"is_preprint":false},{"pmid":"2037301","id":"PMC_2037301","title":"Genetic mapping of the gene for a novel tyrosine kinase, Blk, to mouse chromosome 14.","date":"1991","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/2037301","citation_count":6,"is_preprint":false},{"pmid":"38408513","id":"PMC_38408513","title":"Fyn, Blk, and Lyn kinase inhibitors: A mini-review on medicinal attributes, research progress, and future insights.","date":"2024","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/38408513","citation_count":5,"is_preprint":false},{"pmid":"36233442","id":"PMC_36233442","title":"IgA Vasculitis: Influence of CD40, BLK and BANK1 Gene Polymorphisms.","date":"2022","source":"Journal of clinical medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36233442","citation_count":4,"is_preprint":false},{"pmid":"34952433","id":"PMC_34952433","title":"Discovery of selective irreversible inhibitors of B-Lymphoid tyrosine kinase (BLK).","date":"2021","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34952433","citation_count":4,"is_preprint":false},{"pmid":"12406557","id":"PMC_12406557","title":"Mouse DAM1 regulates pro-apoptotic activity of BLK in mammary epithelial cells.","date":"2002","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/12406557","citation_count":4,"is_preprint":false},{"pmid":"38078859","id":"PMC_38078859","title":"BLK positively regulates TLR/IL-1R signaling by catalyzing TOLLIP phosphorylation.","date":"2023","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/38078859","citation_count":3,"is_preprint":false},{"pmid":"34064199","id":"PMC_34064199","title":"Combined Single Nucleotide Variants of ORAI1 and BLK in a Child with Refractory Kawasaki Disease.","date":"2021","source":"Children (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/34064199","citation_count":2,"is_preprint":false},{"pmid":"31516031","id":"PMC_31516031","title":"'Piperazining' the catalytic gatekeepers: unraveling the pan-inhibition of SRC kinases; LYN, FYN and BLK by masitinib.","date":"2019","source":"Future medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/31516031","citation_count":1,"is_preprint":false},{"pmid":"39417739","id":"PMC_39417739","title":"Association of BLK and BANK1 gene polymorphisms with systemic lupus erythematous in Egyptian patients.","date":"2024","source":"The Egyptian journal of immunology","url":"https://pubmed.ncbi.nlm.nih.gov/39417739","citation_count":0,"is_preprint":false},{"pmid":"41174819","id":"PMC_41174819","title":"FAK-dependent activation of src family kinase member BLK contributed to endometrial fibrosis via endoplasmic reticulum stress.","date":"2025","source":"Cell & bioscience","url":"https://pubmed.ncbi.nlm.nih.gov/41174819","citation_count":0,"is_preprint":false},{"pmid":"39754319","id":"PMC_39754319","title":"A novel BLK heterozygous mutation (p.Met121lle) in maturity-onset diabetes mellitus: A case report and literature review.","date":"2025","source":"Diabetic medicine : a journal of the British Diabetic Association","url":"https://pubmed.ncbi.nlm.nih.gov/39754319","citation_count":0,"is_preprint":false},{"pmid":"36682035","id":"PMC_36682035","title":"The survival rate of laryngeal squamous cell carcinoma: impact of IL1RAP rs4624606, IL1RL1 rs1041973, IL-6 rs1800795, BLK rs13277113, and TIMP3 rs9621532 single nucleotide polymorphisms.","date":"2023","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/36682035","citation_count":0,"is_preprint":false},{"pmid":"41250293","id":"PMC_41250293","title":"Exploration of the regulatory function of genetic variants at FAM167A-BLK locus in systemic lupus erythematosus.","date":"2025","source":"Yi chuan = Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/41250293","citation_count":0,"is_preprint":false},{"pmid":"41153735","id":"PMC_41153735","title":"Rare BLK, CEL, KLF11, PDX1, and PAX4 Gene Variants in Russian Patients with Monogenic Diabetes: Clinical and Molecular Characterization.","date":"2025","source":"Biomedicines","url":"https://pubmed.ncbi.nlm.nih.gov/41153735","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.05.20.655210","title":"Integrating Single-Cell Biophysical and Transcriptomic Features to Resolve Functional Heterogeneity in Mantle Cell Lymphoma","date":"2025-05-24","source":"bioRxiv","url":"https://doi.org/10.1101/2025.05.20.655210","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.18.25324218","title":"Genome-wide association study of dry eye disease reveals shared heritability with systemic comorbidities","date":"2025-03-20","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.18.25324218","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.07.10.602881","title":"Inhibitor-induced supercharging of kinase turnover via endogenous proteolytic circuits","date":"2024-07-10","source":"bioRxiv","url":"https://doi.org/10.1101/2024.07.10.602881","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2024.05.20.24307619","title":"Genetic Variants and Therapeutic Approaches in Maturity-Onset Diabetes of the Young: A Retrospective Analysis","date":"2024-05-20","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.20.24307619","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":49708,"output_tokens":7623,"usd":0.131735},"stage2":{"model":"claude-opus-4-6","input_tokens":11452,"output_tokens":4040,"usd":0.23739},"total_usd":0.369125,"stage1_batch_id":"msgbatch_01TqNM6p6FsoMBT2jzQTwKBr","stage2_batch_id":"msgbatch_01Ya473eco8sTHbvRymQaU8o","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1990,\n      \"finding\": \"BLK (B lymphoid kinase) encodes a 55 kDa Src-family protein tyrosine kinase specifically expressed in B lymphoid cells; the protein exhibits tyrosine kinase activity when expressed in bacterial cells.\",\n      \"method\": \"cDNA cloning, in vitro kinase activity assay in bacterial expression system\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original biochemical characterization with in vitro kinase assay; foundational paper with 238 citations\",\n      \"pmids\": [\"2404338\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1992,\n      \"finding\": \"BLK gene expression is regulated during B-cell development: blk RNA is expressed in pro-B, pre-B, and mature B cells but is absent from plasma cell lines; this developmental-stage specificity is regulated at least in part by changes in transcription rate.\",\n      \"method\": \"Nuclear run-on transcription assay, primer extension, S1 nuclease protection, immunolocalization\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal methods (run-on, nuclease protection, immunolocalization) in single study\",\n      \"pmids\": [\"1537861\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"BLK tyrosine kinase activity is required for anti-IgM-mediated growth inhibition and apoptosis in B-cell lymphoma; antisense oligonucleotides to blk prevent anti-mu-chain-mediated growth arrest and apoptosis without affecting TGF-β-mediated arrest.\",\n      \"method\": \"Antisense oligonucleotide knockdown, cell growth inhibition assay, in vitro kinase assay\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — antisense knockdown with specific phenotypic readout and kinase activity measurement\",\n      \"pmids\": [\"7690139\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"The SH2 domains of BLK, Lyn, and Fyn(T) bind distinct sets of phosphoproteins from B lymphocytes in a phosphotyrosine-dependent manner; BLK SH2 domain preferentially binds phosphoproteins of 90, 130, and 150 kDa whose tyrosine phosphorylation increases after antigen receptor cross-linking.\",\n      \"method\": \"SH2 domain pulldown assay from B-cell lysates, phosphoamino acid analysis, chimeric SH2 domain binding assays\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro pulldown with chimeric domain mutagenesis and phosphoamino acid analysis\",\n      \"pmids\": [\"8226767\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"The BLK promoter is specifically bound by the B-cell-specific activator protein BSAP (PAX5), which acts as a positive transcriptional regulator of BLK expression in B-lymphoid cells.\",\n      \"method\": \"Gel mobility shift assay, competition with known BSAP sites, anti-BSAP antibody supershift, transient transfection reporter assay\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal binding and functional assays identifying BSAP as BLK promoter activator\",\n      \"pmids\": [\"8195169\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"Proteins binding to BLK and Fyn SH2 domains are constitutively tyrosine-phosphorylated in unstimulated pre-B cells, but only appear upon antigen-receptor ligation in mature B cells, suggesting distinct constitutive signaling through the pre-BCR.\",\n      \"method\": \"SH2 domain pulldown from pre-B and B cell lysates (unstimulated and anti-IgM stimulated)\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single pulldown method, but provides novel mechanistic insight into pre-BCR signaling context\",\n      \"pmids\": [\"7514299\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"BLK preferentially phosphorylates peptide substrates with the consensus I/L-Y-D/E-X-L, resembling ITAM motifs found in Igα and Igβ components of the B-cell receptor; BLK requires hydrophobic residue (I/L) at position −1 and negatively charged residue at position +1 relative to the phosphorylated tyrosine.\",\n      \"method\": \"Phage display peptide library selection after in vitro phosphorylation, substrate sequence enrichment analysis\",\n      \"journal\": \"Journal of Molecular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — phage display with in vitro kinase assay; rigorous substrate specificity determination\",\n      \"pmids\": [\"8709147\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"Activated BLK expression in early B and T lymphoid progenitors induces malignant transformation: constitutively active Blk(Y495F) transgenic mice develop B lymphoid tumors with pro-B/pre-B phenotype and clonal thymic lymphomas, indicating BLK controls proliferation during lymphocyte development.\",\n      \"method\": \"Transgenic mouse model with constitutively active Blk(Y495F) mutant; tumor phenotyping by flow cytometry\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo gain-of-function model with specific tumor phenotype and clonality analysis\",\n      \"pmids\": [\"9636152\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"CD72 ligation on B cells activates Lyn and BLK (but not Syk) tyrosine kinases, while also activating BTK; BTK can substitute for Syk in inducing PLC-γ2 tyrosine phosphorylation and calcium mobilization in CD72-stimulated B cells.\",\n      \"method\": \"In vitro kinase assay on immunoprecipitated BLK and Lyn from CD72-ligated B cells; comparison with BCR signaling\",\n      \"journal\": \"Journal of Immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase activity measured by in vitro assay with immunoprecipitation\",\n      \"pmids\": [\"9531290\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Activated BLK is preferentially degraded by the ubiquitin-proteasome pathway; its ubiquitination is mediated by E6AP (an E3 ubiquitin protein ligase), establishing ubiquitin-mediated proteolysis as a regulatory mechanism for BLK activity.\",\n      \"method\": \"Co-immunoprecipitation of E6AP with Src-family kinases, ubiquitination assay, proteasome inhibitor experiments\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP plus functional ubiquitination assay; replicated with multiple Src family members\",\n      \"pmids\": [\"10449731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"AML1 (RUNX1) binds specifically to a site in the BLK promoter through its runt DNA-binding domain and physically interacts with the paired DNA-binding domain of BSAP; AML1 and BSAP synergistically activate BLK promoter transcription by more than 50-fold.\",\n      \"method\": \"Gel mobility shift assay, in vitro binding/pulldown, transient transfection reporter assay\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro protein-protein interaction plus functional synergy demonstrated by reporter assay\",\n      \"pmids\": [\"10455134\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"NF-κB/p50 homodimer interacts with a sequence overlapping the PAX5 binding site on the BLK promoter in LPS-activated B cells and plasma cells; p50 homodimers and p50/p65 heterodimers have opposing effects on BLK transcription, providing a mechanism for differential regulation during B-cell development.\",\n      \"method\": \"Electrophoretic mobility shift assay (EMSA), site-specific mutagenesis, CAT reporter transfection, PAX5 overexpression\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — EMSA with antibody identification, mutagenesis of binding site, and functional reporter assay\",\n      \"pmids\": [\"9660839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"BLK is dispensable for B-cell development, in vitro activation, and humoral immune responses to T-cell-dependent and -independent antigens in mice; Blk knockout mice show no B-cell phenotype, consistent with functional redundancy among Src family kinases.\",\n      \"method\": \"Gene targeting/knockout mouse model, B-cell subset analysis, in vitro activation assays, immunization experiments\",\n      \"journal\": \"Molecular and Cellular Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — complete knockout with comprehensive phenotypic analysis; independently generated mouse model\",\n      \"pmids\": [\"10648608\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"Activated BLK mimics pre-BCR signaling: expression of an active Blk mutant in B progenitors causes proliferation, supports maturation beyond the pro-B stage in pre-BCR-deficient mice, suppresses VH-to-DJH rearrangement, relieves selection for productive heavy-chain rearrangement, stimulates kappa rearrangement, and induces tyrosine phosphorylation of Igβ and Syk.\",\n      \"method\": \"Transgenic active Blk expression in pre-BCR-deficient mice; flow cytometry for B-cell subsets; tyrosine phosphorylation analysis\",\n      \"journal\": \"The Journal of Experimental Medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with multiple defined phenotypic readouts; strong mechanistic study\",\n      \"pmids\": [\"14662906\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2004,\n      \"finding\": \"NERF-2 (ELF-2 isoform) physically interacts with AML1 via a basic region upstream of the Ets domain to cooperatively activate the BLK promoter; the inhibitory isoform NERF-1a interacts with AML1 via the same domain to repress AML1-mediated BLK transcription.\",\n      \"method\": \"In vitro binding assay, co-immunoprecipitation, transient transfection reporter assay, domain mapping\",\n      \"journal\": \"The Journal of Biological Chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro binding confirmed with functional reporter; domain mapping of interaction sites\",\n      \"pmids\": [\"14970218\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"BLK is expressed in pancreatic beta cells where it enhances insulin synthesis and secretion in response to glucose by up-regulating transcription factors Pdx1 and Nkx6.1; the Ala71Thr mutation greatly attenuates these functions.\",\n      \"method\": \"BLK expression in beta cell lines, glucose-stimulated insulin secretion assay, Pdx1/Nkx6.1 reporter assay, mutagenesis\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — functional cell-based assays with mutagenesis showing mechanism; foundational paper for BLK in beta cells\",\n      \"pmids\": [\"19667185\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BLK and BANK1 physically interact (co-immunoprecipitate) in Daudi cells and primary naive B cells; this interaction is enhanced upon BCR stimulation with anti-IgM antibodies.\",\n      \"method\": \"Co-immunoprecipitation, confocal microscopy co-localization\",\n      \"journal\": \"Annals of the Rheumatic Diseases\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP with stimulus-dependence shown; co-localization confirmed by microscopy\",\n      \"pmids\": [\"21978998\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"BLK haploinsufficiency and deficiency impair the generation of marginal zone (MZ) B cells; MZ B cells from Blk-mutant mice are hyper-responsive to BCR stimulation both in vitro and in vivo, revealing a role for BLK in MZ B-cell development and activation threshold.\",\n      \"method\": \"Blk heterozygous and knockout mouse analysis, flow cytometry for B-cell subsets, in vitro BCR stimulation assays\",\n      \"journal\": \"Immunology and Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean genetic model with multiple readouts (development + functional response); moderate evidence\",\n      \"pmids\": [\"21894171\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"BCR-ABL downregulates BLK through c-Myc in CML leukemic stem cells; BLK functions as a tumor suppressor in leukemic stem cells through a pathway involving upstream regulator Pax5 and downstream effector p27, suppressing LSC function without affecting normal hematopoietic stem cells.\",\n      \"method\": \"Retroviral gene expression, shRNA knockdown in CML mouse model, genetic epistasis (Pax5-BLK-p27), human CML stem cell proliferation assay\",\n      \"journal\": \"Nature Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — epistasis pathway defined in vivo with multiple molecular and cellular readouts; replicated in human cells\",\n      \"pmids\": [\"22797726\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The SLE-associated Ala71Thr substitution in BLK decreases protein half-life; NFκB p50 and p65 bind to an associated 1.2 kb haplotype segment in the BLK promoter region, with the risk haplotype showing reduced BLK mRNA levels.\",\n      \"method\": \"Protein stability assay with cycloheximide and western blot, ChIP-qPCR for NF-κB binding, transfection of BLK constructs in HEK293 cells\",\n      \"journal\": \"Annals of the Rheumatic Diseases\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — protein stability assay with mutagenesis plus ChIP validation; multiple orthogonal methods\",\n      \"pmids\": [\"22696686\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"BANK1 and BLK act through phospholipase C gamma 2 (PLCγ2) in B-cell signaling: PLCγ2 interacts with BANK1 (identified by Y2H), and BLK kinase activity enhances BANK1-PLCγ2 binding; interaction is suppressed upon BLK depletion and requires specific tyrosine and proline residues on BANK1.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, mutational analysis of BANK1 tyrosine/proline residues, BCR stimulation\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — Y2H confirmed by Co-IP with mutational analysis; multiple orthogonal methods\",\n      \"pmids\": [\"23555801\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"BLK acts downstream of activated Gα13 to phosphorylate p190RhoGAP, causing RhoA inactivation and deficient cell invasion in response to CXCL12; BLK binds Gα13, and BLK-mediated p190RhoGAP phosphorylation upon Gα13 activation correlates with weakening of Gα13-BLK association and increased BLK-p190RhoGAP assembly.\",\n      \"method\": \"RNAi knockdown, protein overexpression, co-immunoprecipitation, RhoA activation assay, invasion assay\",\n      \"journal\": \"Cellular Signalling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP defining complex assembly, RNAi epistasis, functional invasion assay; multiple orthogonal methods\",\n      \"pmids\": [\"25025568\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"BLK risk haplotype (associated with reduced BLK expression) leads to lower basal BCR signaling but hyperactivatable B cells: enhanced CD86 up-regulation after BCR crosslinking, greater T cell stimulatory capacity, and increased isotype-switched memory B cells.\",\n      \"method\": \"Primary human B cells from RA patients/healthy donors stratified by BLK haplotype, flow cytometry, BCR crosslinking assays, cell culture\",\n      \"journal\": \"Arthritis & Rheumatology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — primary human cells with genotype stratification and multiple functional readouts; single-center study\",\n      \"pmids\": [\"26246128\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"A BLK variant (L3P) found in CVID patients causes reduced BCR crosslinking-induced Syk phosphorylation, impaired B-cell proliferation, accelerated destruction of BCR-internalized antigen, and reduced ability to elicit antigen-specific CD4+ T-cell responses.\",\n      \"method\": \"Functional analysis of L3P-BLK in primary B cells and B-LCLs, Syk phosphorylation assay, antigen presentation assay, proliferation assay\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — natural variant with multiple functional readouts in primary human cells\",\n      \"pmids\": [\"25926555\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"The Ala71Thr variant in BLK SH3 domain causes hyperphosphorylation and kinase activation, leading to enhanced ubiquitination and proteasomal degradation (reduced protein half-life by half); the 71Thr variant also severely reduces binding to the adaptor protein BANK1.\",\n      \"method\": \"In vitro protein stability assay, ubiquitination assay, co-immunoprecipitation of BLK and BANK1, mutagenesis\",\n      \"journal\": \"Genes and Immunity\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis + protein stability + ubiquitination + Co-IP; multiple orthogonal methods in single study\",\n      \"pmids\": [\"26821283\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Ibrutinib inhibits pre-BCR+ B-ALL progression by targeting both BTK and BLK; CRISPR-Cas9 gene editing of BTK and BLK individually demonstrated both are relevant ibrutinib targets in pre-BCR+ ALL, with inhibition deactivating PI3K/Akt signaling and reducing BCL6 levels.\",\n      \"method\": \"CRISPR-Cas9 gene editing, drug sensitivity assays, PI3K/Akt signaling analysis, mouse xenograft model\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — CRISPR-Cas9 genetic validation of BLK as ibrutinib target in vivo and in vitro\",\n      \"pmids\": [\"28031181\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Bakuchiol directly binds to BLK kinase in an ATP-competitive manner and inhibits EGF-induced signaling pathways including MEK/ERK, p38 MAPK/MSK1, and AKT/p70S6K downstream of BLK.\",\n      \"method\": \"Kinase profiling, direct binding assay (ATP-competitive), in vitro kinase assay, in vivo xenograft\",\n      \"journal\": \"Oncotarget\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding and kinase assay; but primarily a pharmacological study with BLK as one of multiple targets\",\n      \"pmids\": [\"26910280\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Rare missense variants in BLK found in SLE patients (but not controls) impair suppression of IRF5 and type-I IFN in human B cell lines and increase pathogenic lymphocytes in lupus-prone mice; BLK and BANK1 interact physically and functionally to regulate these pathways.\",\n      \"method\": \"Functional assay of rare variants in B cell lines (IRF5/IFN suppression), lupus-prone mouse model with variant introduction, Co-IP\",\n      \"journal\": \"Nature Communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional validation of specific rare variants in human B cells and in vivo mouse model; strong evidence\",\n      \"pmids\": [\"31101814\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BLK phosphorylates IRF3 at tyrosine 107 following viral infection; BLK first undergoes autophosphorylation at Y309 upon viral infection, then directly binds and phosphorylates IRF3-Y107, which promotes TBK1-induced IRF3 S386/S396 phosphorylation and downstream antiviral response; BLK-deficient mice show lower serum cytokines and higher lethality after VSV infection.\",\n      \"method\": \"In vitro kinase assay, mutagenesis (Y309 and Y107), co-immunoprecipitation, BLK knockout cells and mice, viral infection models\",\n      \"journal\": \"PLoS Pathogens\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay with site mutagenesis, Co-IP, and in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"37871014\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BLK is pre-associated with IL1R1 and IL1RAcP in resting cells; IL-1β stimulation induces BLK autophosphorylation at Y309, after which activated BLK directly phosphorylates TOLLIP at Y76/86/152, promoting TOLLIP dissociation from IRAK1 and facilitating TLR/IL-1R-mediated signal transduction.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, mutagenesis (Y309, Y76/86/152), BLK-deficient mice (IL-1β challenge), signaling analysis\",\n      \"journal\": \"The Journal of Cell Biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — in vitro kinase assay with site mutagenesis, Co-IP of receptor complex, in vivo validation; multiple orthogonal methods\",\n      \"pmids\": [\"38078859\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"BLK forms a complex with CLDN6 via the C-terminal cytoplasmic domain through direct protein-protein interaction (independent of phosphotyrosine); BLK is essential for CLDN6-triggered epithelial differentiation and retinoid acid receptor target gene expression.\",\n      \"method\": \"Immunoprecipitation, pull-down assay with recombinant proteins, CRISPR knockout of Blk in F9:Cldn6 cells, gene expression analysis\",\n      \"journal\": \"Cells\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — recombinant protein pulldown confirming direct binding + CRISPR knockout with functional readout\",\n      \"pmids\": [\"37443730\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"BLK is activated by FAK through complex formation in TGF-β1-induced endometrial stromal cells; FAK-BLK complex formation leads to BLK phospho-activation, which drives endoplasmic reticulum stress (GRP78/CHOP upregulation) and endometrial fibrosis; BLK knockdown attenuates fibrosis in vitro and in an intrauterine adhesion mouse model.\",\n      \"method\": \"Co-immunoprecipitation (FAK-BLK complex), siRNA knockdown, in vivo Blk knockdown mouse model, ERS marker analysis\",\n      \"journal\": \"Cell & Bioscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP and in vivo knockdown with defined molecular pathway; single study\",\n      \"pmids\": [\"41174819\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2002,\n      \"finding\": \"Mouse DAM1 interacts with BLK (identified by yeast two-hybrid) and confirmed by in vitro protein binding assay; co-expression of mDAM1 and BLK increases cell death compared to BLK alone in mammary epithelial cells, indicating mDAM1 promotes BLK pro-apoptotic function.\",\n      \"method\": \"Yeast two-hybrid screening, in vitro protein binding assay, stable transfection, cell death assay\",\n      \"journal\": \"Cancer Letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — Y2H confirmed by in vitro binding with functional co-expression data; single study\",\n      \"pmids\": [\"12406557\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Two lupus-associated BLK promoter variants are functionally causal: rs922483 in the proximal BLK promoter reduces promoter activity and modulates alternative promoter usage; rs1382568 (tri-allelic) in the upstream alternative BLK promoter alters promoter activity in B progenitor cell lines.\",\n      \"method\": \"Trans-population mapping, sequencing, luciferase reporter assay in B cell lines\",\n      \"journal\": \"American Journal of Human Genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — functional promoter reporter assay with two independent variants; cell-type-specific validation\",\n      \"pmids\": [\"24702955\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"BLK is a B-lymphoid-specific Src-family non-receptor tyrosine kinase whose expression is controlled by BSAP/PAX5, AML1/RUNX1, NF-κB, and NERF/ELF-2 transcription factors; it signals downstream of the BCR and pre-BCR (phosphorylating Igβ and activating Syk), interacts physically with BANK1 (via its SH3 domain) and PLCγ2 to regulate B-cell activation, is degraded by E6AP-mediated ubiquitin-proteasome proteolysis when activated, phosphorylates IRF3 at Y107 and TOLLIP at Y76/86/152 to promote antiviral and TLR/IL-1R innate immune signaling, acts downstream of Gα13 to phosphorylate p190RhoGAP and inhibit RhoA-driven cell invasion, forms a complex with FAK to drive endoplasmic reticulum stress in fibrosis, and functions as a tumor suppressor in CML leukemic stem cells through a Pax5-BLK-p27 pathway.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"BLK is a B-lymphoid Src-family non-receptor tyrosine kinase that transduces signals from the B-cell receptor and pre-BCR, phosphorylating Igβ ITAMs and activating Syk to regulate B-cell development, activation thresholds, and immunoglobulin gene rearrangement [PMID:14662906, PMID:8709147, PMID:25926555]. Its expression is transcriptionally controlled by PAX5/BSAP, RUNX1/AML1, NF-κB, and NERF-2/ELF-2, which synergistically regulate the BLK promoter during B-cell differentiation, while activated BLK protein is turned over via E6AP-mediated ubiquitin-proteasome degradation [PMID:8195169, PMID:10455134, PMID:10449731]. Beyond canonical BCR signaling—where BLK cooperates with BANK1 and PLCγ2 to modulate B-cell activation and suppress IRF5/type-I IFN pathways relevant to lupus [PMID:23555801, PMID:31101814]—BLK phosphorylates IRF3-Y107 to promote antiviral innate immunity and phosphorylates TOLLIP-Y76/86/152 to facilitate TLR/IL-1R signaling [PMID:37871014, PMID:38078859]. BLK also functions as a tumor suppressor in CML leukemic stem cells through a Pax5–BLK–p27 axis, acts downstream of Gα13 to phosphorylate p190RhoGAP and inhibit RhoA-driven invasion, and enhances insulin synthesis in pancreatic β-cells by upregulating Pdx1 and Nkx6.1 [PMID:22797726, PMID:25025568, PMID:19667185].\",\n  \"teleology\": [\n    {\n      \"year\": 1990,\n      \"claim\": \"Identification of BLK as a B-lymphoid-specific Src-family tyrosine kinase established the existence of a lineage-restricted kinase that could mediate B-cell-specific signaling events.\",\n      \"evidence\": \"cDNA cloning and in vitro kinase assay in bacterial expression system\",\n      \"pmids\": [\"2404338\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No substrates or signaling pathway identified\", \"In vivo function unknown\"]\n    },\n    {\n      \"year\": 1993,\n      \"claim\": \"Demonstrating that BLK kinase activity is required for anti-IgM-induced growth arrest and apoptosis in B-cell lymphoma, and that its SH2 domain binds distinct BCR-stimulated phosphoproteins, linked BLK functionally to BCR signaling.\",\n      \"evidence\": \"Antisense knockdown with growth/apoptosis readout; SH2 domain pulldowns from B-cell lysates with phosphoamino acid analysis\",\n      \"pmids\": [\"7690139\", \"8226767\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct substrates not yet identified\", \"Relationship to other Src kinases in BCR signaling unclear\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Determination of BLK's substrate consensus motif (I/L-Y-D/E-X-L) matching Igα/Igβ ITAMs identified the likely physiological substrates linking BLK to BCR complex phosphorylation.\",\n      \"evidence\": \"Phage display peptide library selection with in vitro phosphorylation\",\n      \"pmids\": [\"8709147\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of Igβ ITAMs not yet shown in cells\", \"Relative contribution versus Lyn unknown\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Mapping the transcriptional control of BLK by PAX5/BSAP, NF-κB p50/p65, and later AML1/RUNX1 and NERF-2 explained how BLK expression is restricted to B-lymphoid cells and modulated during differentiation, including downregulation in plasma cells.\",\n      \"evidence\": \"EMSA, supershift, mutagenesis, reporter assays across multiple studies; synergistic activation by AML1+BSAP (>50-fold)\",\n      \"pmids\": [\"8195169\", \"9660839\", \"10455134\", \"14970218\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Epigenetic regulation not addressed\", \"In vivo promoter occupancy dynamics during B-cell differentiation not mapped\"]\n    },\n    {\n      \"year\": 1998,\n      \"claim\": \"Constitutively active Blk(Y495F) transgenic mice developed B-lymphoid and thymic tumors, revealing that uncontrolled BLK signaling is oncogenic during lymphoid development and establishing the need for tight regulation of BLK activity.\",\n      \"evidence\": \"Transgenic mouse model with gain-of-function Blk mutant; tumor phenotyping by flow cytometry\",\n      \"pmids\": [\"9636152\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Downstream oncogenic effectors not identified\", \"Whether kinase-dead rescue prevents tumorigenesis not tested\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that activated BLK is degraded via E6AP-mediated ubiquitin-proteasome proteolysis provided the mechanism for limiting BLK kinase activity, explaining how BLK turnover is coupled to its activation state.\",\n      \"evidence\": \"Co-immunoprecipitation of E6AP with Src-family kinases, ubiquitination assay, proteasome inhibitor experiments\",\n      \"pmids\": [\"10449731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Specific ubiquitination sites on BLK not mapped\", \"Whether E6AP loss affects B-cell phenotype through BLK stabilization not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The absence of a B-cell developmental phenotype in Blk knockout mice demonstrated functional redundancy among Src-family kinases, but left open the question of BLK's non-redundant roles.\",\n      \"evidence\": \"Gene targeting/knockout mouse with comprehensive B-cell subset and humoral immunity analysis\",\n      \"pmids\": [\"10648608\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Compound knockouts with Lyn/Fyn not tested\", \"Marginal zone B-cell subset not specifically examined\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Active BLK was shown to substitute for pre-BCR signaling in vivo—driving Igβ/Syk phosphorylation, B-cell maturation past the pro-B stage, and immunoglobulin gene rearrangement—establishing BLK as a critical kinase linking the pre-BCR to developmental checkpoints.\",\n      \"evidence\": \"Transgenic active Blk expression in pre-BCR-deficient mice with flow cytometry and phosphorylation analysis\",\n      \"pmids\": [\"14662906\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether endogenous BLK (not constitutively active) is the dominant pre-BCR kinase remains unclear\", \"Signaling intermediates between Syk activation and gene rearrangement not defined\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Discovery of BLK expression and function in pancreatic β-cells, where it enhances insulin synthesis/secretion by upregulating Pdx1 and Nkx6.1, expanded BLK's biological roles beyond the immune system and linked the Ala71Thr variant to impaired β-cell function.\",\n      \"evidence\": \"BLK expression in beta cell lines, glucose-stimulated insulin secretion assay, Pdx1/Nkx6.1 reporter assay, mutagenesis\",\n      \"pmids\": [\"19667185\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct kinase substrates in β-cells not identified\", \"Mechanism linking BLK kinase activity to Pdx1/Nkx6.1 transcription unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"BLK was identified as a tumor suppressor in CML leukemic stem cells, operating through a Pax5–BLK–p27 axis that is silenced by BCR-ABL/c-Myc, providing a mechanism for leukemic stem cell self-renewal and a rationale for reactivating BLK in CML therapy.\",\n      \"evidence\": \"Retroviral expression, shRNA knockdown in CML mouse model, genetic epistasis, human CML stem cell assays\",\n      \"pmids\": [\"22797726\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BLK upregulates p27 mechanistically not defined\", \"Whether BLK reactivation is therapeutically feasible not addressed\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Elucidation of the BLK–BANK1–PLCγ2 signaling module downstream of the BCR revealed how BLK kinase activity promotes BANK1–PLCγ2 complex assembly, and how disease-associated variants in BLK and BANK1 disrupt this pathway.\",\n      \"evidence\": \"Yeast two-hybrid, co-immunoprecipitation, mutational analysis of BANK1 tyrosine/proline residues\",\n      \"pmids\": [\"23555801\", \"21978998\", \"26821283\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether BANK1 is a direct BLK substrate not proven by in vitro kinase assay\", \"Downstream consequences of PLCγ2 activation specificity via this module not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of BLK as a Gα13 effector that phosphorylates p190RhoGAP to inactivate RhoA revealed a non-BCR signaling axis controlling cell invasion, broadening BLK's mechanistic repertoire beyond lymphocyte biology.\",\n      \"evidence\": \"RNAi knockdown, co-immunoprecipitation, RhoA activation assay, invasion assay\",\n      \"pmids\": [\"25025568\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Physiological context for Gα13–BLK axis in B cells not established\", \"Whether this pathway operates in vivo not tested\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"CRISPR-Cas9 validation that both BLK and BTK are functional ibrutinib targets in pre-BCR+ B-ALL established BLK as a therapeutic target in acute lymphoblastic leukemia, with inhibition deactivating PI3K/Akt signaling.\",\n      \"evidence\": \"CRISPR-Cas9 gene editing of BTK and BLK individually, drug sensitivity assays, mouse xenograft model\",\n      \"pmids\": [\"28031181\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of BLK vs BTK inhibition to clinical ibrutinib efficacy unknown\", \"BLK-specific inhibitors not available\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Rare SLE-associated BLK variants were shown to impair suppression of IRF5 and type-I IFN, with BLK and BANK1 functioning together to restrain this pathway, establishing a direct mechanistic link between BLK loss-of-function and lupus pathogenesis.\",\n      \"evidence\": \"Functional assay of rare variants in human B cell lines, lupus-prone mouse model, co-immunoprecipitation\",\n      \"pmids\": [\"31101814\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How BLK kinase activity suppresses IRF5 mechanistically not defined\", \"Whether this pathway is B-cell-intrinsic or involves other cell types not resolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"BLK was established as a direct kinase for IRF3 (at Y107) in antiviral innate immunity and for TOLLIP (at Y76/86/152) in TLR/IL-1R signaling, revealing BLK as a broadly active innate immune signaling kinase beyond its classical BCR role.\",\n      \"evidence\": \"In vitro kinase assays with site-directed mutagenesis, co-immunoprecipitation of receptor complexes, BLK knockout mice with viral/IL-1β challenge\",\n      \"pmids\": [\"37871014\", \"38078859\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Cell types responsible for BLK-mediated innate immunity in vivo not defined\", \"Whether BLK phosphorylation of IRF3 and TOLLIP occurs in the same or different cell contexts unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"FAK was identified as an upstream activator that forms a complex with BLK to drive endoplasmic reticulum stress and fibrosis in endometrial stromal cells, extending BLK function to a non-immune fibrotic disease context.\",\n      \"evidence\": \"Co-immunoprecipitation of FAK-BLK, siRNA knockdown, in vivo Blk knockdown in intrauterine adhesion mouse model\",\n      \"pmids\": [\"41174819\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct FAK phosphorylation sites on BLK not mapped\", \"Single study; independent replication needed\", \"Whether BLK–ER stress axis operates in other fibrotic tissues not examined\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include: the structural basis for BLK's substrate selectivity versus other Src-family kinases; the identity of BLK's direct substrates linking it to Pdx1/Nkx6.1 in β-cells and to p27 in CML stem cells; and whether BLK-specific inhibitors can be developed for therapeutic applications.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of BLK\", \"No BLK-specific small-molecule inhibitor characterized\", \"In vivo compound Src-family kinase knockouts needed to define non-redundant BLK functions\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 6, 13, 21, 28, 29]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [18, 27]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [3, 16, 20]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [29, 30]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"GO:0162582\", \"supporting_discovery_ids\": [2, 3, 13, 20, 21, 25]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [13, 17, 27, 28, 29]},\n      {\"term_id\": \"R-HSA-5357801\", \"supporting_discovery_ids\": [2, 32]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [21, 25, 26]}\n    ],\n    \"complexes\": [\n      \"pre-BCR signaling complex\",\n      \"BANK1-BLK-PLCγ2 module\",\n      \"IL-1R1/IL1RAcP-BLK complex\"\n    ],\n    \"partners\": [\n      \"BANK1\",\n      \"PLCG2\",\n      \"E6AP\",\n      \"FAK\",\n      \"CLDN6\",\n      \"GNA13\",\n      \"IRF3\",\n      \"TOLLIP\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}